Xlife Sciences AG (XSWX:XLS) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Xlife Sciences AG's Enterprise Value for the quarter that ended in Dec. 2025 was CHF287.25 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Xlife Sciences AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-31.41 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xlife Sciences AG EV-to-EBIT Related Terms
Xlife Sciences AG EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Xlife Sciences AG's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:XLS vs VRTX, REGN, ALNY: EV-to-EBIT Comparison
For the Biotechnology subindustry, Xlife Sciences AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xlife Sciences AG EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Xlife Sciences AG's EV-to-EBIT falls into.
Xlife Sciences AG's current Enterprise Value is CHF249.46 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Xlife Sciences AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-31.41 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xlife Sciences AG (XSWX:XLS) has a EV-to-EBIT of -7.94 as of Jul. 07, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Xlife Sciences AG and its competitors. According to the industry distribution chart, Xlife Sciences AG ranks #999999 out of 367 companies in the Biotechnology industry.
Is Xlife Sciences AG's EV-to-EBIT too high?
Xlife Sciences AG's current EV-to-EBIT is -7.94. Based on the distribution chart, Xlife Sciences AG ranks #999999 out of 367 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Xlife Sciences AG has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xlife Sciences AG ranks #999999 out of 367 companies for EV-to-EBIT. This places Xlife Sciences AG in the lower half of its industry. The industry median EV-to-EBIT is 14.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 14.56, based on 367 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Xlife Sciences AG and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 14.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xlife Sciences AG's current EV-to-EBIT is -7.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.25, compared to a current price of CHF18.15 — trading 150.3% above its estimated fair value. The current EV-to-EBIT is -7.94. Xlife Sciences AG's overall GF Score™ is 53/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current EV-to-EBIT is -7.94 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?
Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued.
The current stock price of CHF18.15 is trading 150.3% above its estimated GF Value™ of CHF7.25.
GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.
Key valuation signals for XSWX:XLS:
EV-to-EBIT: -7.94
GF Value™: CHF7.25 vs. price of CHF18.15 (150.3% above fair value)
No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
53GF Score
Get the complete analysis for XSWX:XLS
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:XLS has been successfully added to your 
